{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Therapeutic Update on Neuromuscular Disorders Conference Highlights from 2018
Activity Steps
Description
To access this FREE activity, please login (or register first in a new tab). After login, click on the blue +Cart button and enter the Coupon Code: NMDFREE What are the most important recent developments in the treatment of spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD)? In this 1-hour educational webcast, two leading experts review the latest data presented at major conferences during 2018. Dr. Basil Darras and Dr. John Brandsema discuss the latest clinical findings relating to new and emerging treatments for SMA and for DMD, and highlight the implications for daily practice. Target Audience This activity has been designed to meet the educational needs of neurologists, neuromuscular disease specialists, pulmonologists, physical therapists, nurses, and other HCPs involved in the management of patients with NMDs
Learning Objectives
After completing this continuing education activity you will be able to:
- List the pathophysiology and classification of different NMDs, and the implications for diagnosis
- Outline the mechanisms of action of current and emerging therapies for NMDs
- Discuss the latest important clinical trial data on current and emerging therapies for spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD)
- Summarize how the new research findings presented at the major neurology conferences could influence the way that HCPs diagnose and treat patients with NMDs.
Disclosures
Dr. Darras has disclosed that he was/is on the speakers bureau for Biogen; was/is a consultant/advisor for AveXis, Inc., Biogen, PTC Therapeutics, Sarepta Therapeutics, Roche, Genentech, and Cytokinetics; was/is a grant/research recipient from AveXis, Inc., Biogen, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Sarepta Therapeutics, Cytokinetics, FibroGen, Inc., Roche, Santhera Pharmaceuticals, Summit, CureSMA, National Institutes of Health/National Institute of Neurological Disorders and Stroke, Slaney Family Fund for SMA, the SMA Foundation, and the Working on Walking Fund
Dr. Brandsema has disclosed that he was/is on the speakers bureau for Biogen; was/is a consultant/advisor for AveXis, Inc., Biogen, PTC Therapeutics, Sarepta Therapeutics, Alexion Pharmaceuticals, Inc., Cytokinetics; was/is a grant/research support recipient for AveXis, Inc., Biogen, PTC Therapeutics, Sarepta Therapeutics, Alexion Pharmaceuticals, Inc., Cytokinetics Non-Faculty All planners in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interest in, any commercial organizations pertaining to this educational activity. Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Lippincott CME Institute and Ology Medical Education do not recommend the use of any agent outside of the labeled indications.Financial Support
This activity has been supported by an independent educational grant from Biogen MA, Inc. and PTC Therapeutics, Inc. Method of Participation1. Read the educational objectives, accreditation information, and faculty disclosures. 2. Take the pre-test. 3. Watch the webcast. 4. Take the post-test and complete the evaluation.
Credits:
- ACCME 1.0 CME